平成21年度経済産業省委託事業 平成21年度戦略的技術開発委託費
Contents
1.2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12. WG
13. Gail Framingham
14. QMS Quality Management System
15. 21 CFR 809 10 b 12 6
16. 223
17. Ver XX 1
18. 906 1314 169 0330001
19. I 1 9
20. 126 6 4 dependability
21. 90
22. Ba Ba aw II 1 0
23. 2 1 8 7
24. E
25. RNA R N A
26. Replacement Reduction Refinement 3R 9 7 2 1 WG
27. WG 6 DNA
28. 700 3 ae
29. A 12 JIS T 14971 2003 1S0 14
30. 3
31. 3 1 21 1
32. B WG 10
33. 20 7 WG 1 WG 21 11 18 10 00 12 00
34. TRE TRE 2 7 stand alone Target Registration Error TRE TRE
35. 2 6 1
36. FDA I VDM 167 I A 21 CFR Part 862 Subpart B 21 CFR Part 862 Subpart D I VDM I A F
37. 3596 1696 209 6 159 5 GE 2 WG 1 21 11 25 2 2 1 1 2 2 30 3
38. IEC60601 1 ME Medical Electronics 3 4 1
39. FMEA 3 FMEA FMEA FMEA 2 FMEA
40. http www fda gov down loads MedicalDevices DeviceRegulationandGuidance GuidanceDocumen ts ucm073704 pdf 181 21 CFR 807 Subpart E the act
41. 7 2 3 4 5 6
42. ACR 21 CFR 809 10 b 11 15 192 2 2 1
43. 120150 3 33 4 5 4
44. first priority 106
45. 98 5
46. 2
47. WG WG WG WG WG DNA WG WG B C D F G H IV 1 2 I
48. 211 B mode Flastogram CAD Ee ec 2 3 a 2004 a
49. 1 17 8 4 2 17 9 13 3 18 3 16 WG 4 18 6 15 1 7
50. A 7 10 146
51. 4 3 6 3 WG TF 22 1 25 9 30 12 00 I 2 16 1 2 1F 83 50
52. CH IS013485 JIS Q 13485 IS09000 9001 JIS Q 9000 9001 225 a
53. TRE 3 2 3
54. 134 2
55. WG 2 3 O
56. WG 1S0198 15 2
57. DNA MammaPrint RNA RT PCR Oncotype DX 2 3 RN A RNA
58. 20 WG 20 2 0JT 0JT 0JT 3 2
59. FDA
60. 1 GHTF 1 1994 4 Medical Devices Guidance Document 1998 5 Guidance for the Content of Pre market Submissions for Software Contained in Medical Devices 1999 1 Guidance For the Interpre
61. II 3 6 D
62. 6 5 10 k predicate device F DA
63. BMI WG
64. lt gt 6 1 1 4 4 4
65. CT d 214
66. CT 75 12 6 CT
67. 4 2 WG 2 2 3 1 Sav Gado 1 4 6 5D dd 8 V V 1 15 V 2
68. 3
69. 2 19 ES iPS
70. TF WG
71. 8 2 8 2 1 1S014708 3 6 102 9 9 1 IS014708 3 15
72. I VDM I A I VDM I A FDA F DA I VDM TI A IVDM TI A FDA FDA I VDM I A 164 LDT
73. 142 3 A 1 Ei V1I 5
74. 2 3
75. ACR F DA
76. a b c
77. I VDMI A 166 0O I VDMI A I VDM1IA I VDM I A 0 IV D IVDMTIA IVDM 1IA I VD
78. 3000 4 000 lt 3 500 2500 on ER 3000 2 000 2 500 1 500 2 000 pt 1 500 1 000 1 000 LY 2 500 500 2 0 0 2000 2005 2010 2015 2020 2006 12 2008 1 26 2
79. 188 FDA FDA ACR 1 ACR 2 ACR 3 ACR
80. 235 3 QOL 2 1
81. CAD CADe 1970 ASU 1004 U Systems SomoVu MeDiiSys Imaging Sofia 15cmx 15cm
82. t gt CAD WG WG WG 1 1 WG 2 1 12 15 2 WG 2 2 2 16 2 1 WG 2 1 10 28 12 2 WG 2 1 11 25 3 WG 2 1 12
83. 113
84. 3 RNA 3 RN A
85. 5 D ACR
86. 21 11 26 10 00 15 00 TWIns 1 1 0 1 FATS
87. 6 Critical Path 0pportunities List FDA March 2006 FDA http www fda gov Drugs ScienceResearch ResearchAreas Pharmacogenetics ucm083378 h tm Known Valid Biomarkers FDA EMEA Probable Valid
88. 2015 35 1 2 3 Compression Hip Screw CHS
89. IEC60601 1 99 10 2 1 2 1 M E ME 1m 50mm 5mm gt 600kg m ME ME
90. 6 13 14 76 1 2 3 4 5 6 7 8 9 16 11 15 No 19
91. 2 J I RA CAD 230 4 CAD CAD CADe CADx CADe NWE OEB OMJ X 510K CADx
92. X PS 1 2 2008 2008
93. J START CAD 3D Raw data CAD CAD 3 X CT CAD CAD CAD
94. 1 5 1 7 1 6 4 1 7 5 2 1
95. 2 I VDM 1 A IVDM IA 21 CFR Part 50 21 CFR 809 10 c 2 ij IDE 21 CFR Part 812
96. F DA http www fda gov cdrh modact leastburdensome html
97. 5 3 predicate device 21 CFR 807 87 f FDA
98. JAMIT JAMIT 1995 3 X X CT CT JAMIT 3
99. x 4 69 7 JIS 1 JIS T 3012 2009 2 JIS T 0313 2009 3 JIS T 3011 2009 3 JIS T 3009 2009 4 JIS T 3010 2009 5 JIS T 7401 1 2002 1 6 JIS T 7401 2 2002 2 Ti 6Al 4V 7 JIS T 7401 3 2002 3 Ti 6Al 2Nb 1Ta 8 JIS
100. 120 150 38 7 7 J 1 X X CT
101. lt gt 1
102. 514 c 1 B FDA FDA http www fda gov cdrh ode guidance 1131 html F DA 21 CFR 807 87 510 k 21 CFR 807 87
103. JMAC 2 1 3 WG WG 1 WG WG 3 WG WG 2 WG 4 DNA DNA
104. iv
105. b 3 3
106. i ii iii iv v vi Vii viii cs 22
107. 28 4 5 2 x 2 29 4 1 WG 1 21 10 28 2 1 1
108. FIB FE TEM JIS T 0306 X XPS Ar XPS D 2 XPS JIS T 0302 0 mV
109. CPU 87
110. 3 gt 1 Barbara Steinwachs How to Facilitate a Debriefing Simulation amp Gaming Vol 23 No 2 pp 186 195 1992 2 20 2009 200835058A http mhl WGrants niph go jp Accessed 2010 01 31 3 credentialing prigileging Vol 25 No 6 pp 747 752 2006 148 2009 http www kokken go jp byoin Accessed 2010 01 31
111. IS014708 3 6 101 8 1 2 90 8 1 3
112. FMEA FMEA WG 2 WG 21 12 4 14 00 16 00 5 128
113. 3 1 JIS T 0312 2 JIS T 0313 3 JIS T 0311 4 JIS T 0309 5 JIS T 0310 6 JIS T 7401 1 1 7 JIS T 7401 2 2 Ti 6Al 4V 8 JIS T 7401 3 3 Ti 6Al 2Nb 1Ta 9 JIS T 7401 4 4 Ti 15Zr 4Nb 4Ta 10 JIS T 7401 5 5 Ti 6Al 7Nb 11 JIS T 7401 6
114. I VDM IA I VDM I A I VDM I A I VDM I A 21 CFR 866 6040
115. a a 7 100 2500 gy 24 37 80 2000 742 1 0 4 XU 1000 I 500r 20 EE 9 LTI III 1 1989 1992 1999 2002 2005 2006 2007 2008 2009 ND A 1 1 5 CCC Q 8 8 Q Ey Archives of Orthopaedic and Trauma Surgery Acta Chirurgiae orthopaedicae et Traumatologiae eechoslovace Acta Orthopaedica Clinical Orthopaedics and Related Research International Orthopaedics The Journal of Arthroplasty The Journal of Bone Joint Surgery Am Br Revue Chirurdie Orthop dique et Reparatrice de Appareil Mot Zeitschrift fur Orthopadie und ihre Grenzgebiete 2 67 4
116. 0JT
117. 4 2 1 1S0 14971 JIS T14971 6 3 2
118. 2 2 3 236 2 1 2 1 100 8901 1 3 1 TEL 03 3501 1562 FAX 03 3501 6613 URL http www meti go jp 305 8566 1 1 1 TEL FAX 029 861 70
119. QOL Quality of Life 16 2
120. 0 mV Ti 15Zr 4Nb 4Ta 1 cm2 250 400 1 2 2 0 MQ cmW 10 25 wF 50 1 DP p 136 2 X p 13 3 S Tamura C J Powell D R Penn Surf Interface Anal 21 165 1994 4 N T C
121. 3 2 I SO 3 3 20 4
122. 3 CT 4 CAD 2 3 CAD WG 2 3 1 CAD R2 1998 6 FDA R2 19 2
123. 21 3 C 2 137 2
124. 1 2 1
125. 3 9 5 WG 22 2 24 13 00 15 00 2 L 1 6 8 50 TF 2 15 TF A B
126. 17 3 WG WG 2 3 1 21 1 WG 1 21 12 15 18 00 20 00 2
127. FDA510 k 5 1 0 k 21 CFR 809 10 a 2 b 2
128. HIPAA http aspe os dhhs gov admnsimp 5 1 0 k 5 1 0 k 190
129. 3 2 1 RNA MCF 7 17b estradiol E2 10 nM QIAGEN RNeasy Plus Mini RNA DMSO 2 mRNA R N A RNA DNA 199 RNA aRNA 1 RNA SuperScript RNA Amplification System mRNA 3 cDNA
130. 4 35 169 20 15 5
131. 5 0 m 1ml 100 25m Iml 5 1 8 1 1 1S014708 3 6 101 101 RN R Ri 499 Q 16
132. WG 35 Guideline for development of custom made osteosynthesis devices 1 35 2
133. 1 3 15 2 232 4 2 1 CAD CAD C AD
134. JMAC 1 DNA 2 DNA DNA 161 ISO TC34 SC 1 6
135. 5 DNA I SO TC3 4 SC 1 6 2010 2 9 1 1 I SO TC34 SC16 JMAC
136. 3 0 1 150 V 6 DNA 1 1 1 2003 DNA 9 9 9 2 8 0 00 HUGO 3 0 0
137. 2 1 2 retrospective
138. 102 1 3 2 1 1 4 2 2 1 navigational device
139. 6 C RNA RNA RNA c
140. TRE 108 1 2 3 109 4 4 1 1
141. 2 0 0 9 5 1 2 CYP CYP2C19 3 1 Poor metaboliser 2 Extensive metaboliser 2 CYP2D6 8 2 7 1 Poor metaboliser 2 Intermediate metaboliser 3 Extensive metaboliser 4 Ultra rapid metaboliser 4 Agendia MammaPrint MammaPr int 7 0 2007
142. 1 8 WG 4 6 6 1 2
143. P C PC D ROM
144. 107 3 2 2 TRE JIS Z8103 TRE TRE TRE
145. HISO 14971 JIS T 14971 136
146. RNA RNA 5 1 0 k F DA FDA FDA should
147. BM I Brain Machine Interface D B S TMS Transcranial Magnetic Stimulation BM I 4 1 2
148. WG WG TF WG
149. 139 3 B
150. F D A Substantial Equivalence SE 21 CFR 807 81 807 87 F DA the act A 3 F DA 21 CFR 807 87 5 1 0 k s 510 k
151. 1 4 3 FDA 3 FDA I II T 180 2009 10 2 1 1 TI
152. http dmd nihs go jp jisedai neuro index html 10 10 1 IS014708 3 27 IS014708 3 27 101 93 1S014708 3 27 102 27 106 10 2 IS014708 3 23 10 2 1 3 IEC60601 1 2005 15 3 4 1 10 2 1 1 ME
153. 1 32 6 3 4 5
154. A 1 A 1 20 x A 1 43 B B 1
155. 5 10 k 9596 ACR ACR ACR
156. CD R PC PC PC PC 3
157. 2 4 CAD CAD 1 CAD PACS 2 PC WS CAD 3 CAD 4 5 CAD
158. PMI 3 WG 1 21 12 22 2 3 1 2 3 2 3 2 3 4
159. a Level Set Graph Cuts b c
160. 2 3 3 HFMEA 4 25 10 1 10 117
161. RNA http www fda gov cdrh ode guidance 337 pdf FDA CDRH FD A 8 21 CFR 807 87 e 21 CFR 807 87 e 5 1 0 k
162. JMAC 2 0 1 0 2 0 2 1 195 RNA RNA RNA RNA
163. 111 5 5 1 1 Registration 2 112
164. 4 5 1 1 2 2 5 5 30 4 1 1 6 3 4
165. 5 C 184
166. DNA 2 0 3 cDNA 1 9 2 0 3 DNA DNA cDNA cDNA 1 20 100 6 5
167. c 2
168. 1 D 1 B 1 1 144 20 WG
169. 1 C 1 3 140
170. lt _ gt i PE
171. 2004 CLSI EP5 A2 2 00 2 CLSI EP12 A 2 0 0 4 CLSI EP17 A intra assay inter assay total assay RN A RNA 1 0 178
172. 233 VI RS 1 1 3 2 1SO TC150 TC198
173. LT SD 2 OK 7 0 7 IAIK 74 a b c 5 10 11
174. I V DM I A IVDM IA FDA 21 USC 360 21 CFR Part 807 FDA FDA 2891 FDA 21 CFR 807 22 3 30 F DA 2892 21 CFR 807 22 b I VDM I A I I 21 USC 360 m 5 10 k FDA 5 1 0 k
175. 2 21 USC 321 h I VDM I A 1 2 IVDMTIA IVDMTI A LDT LDT
176. 3
177. 37 Compression Hip Screw CHS 1
178. IVDMIA LDT FDA FD 62 FR 62249 LDT 21 CFR 864 4010 21 CFR 862 2050 21 CFR Part 864 subpart D 21 CFR 862 1660 L DT I VDM I A LDT I VDM I A 1IV DM IA FDA LDT IVDMTIA
179. 6 CAD 1 PACS CAD 2 PACS PC CAD PC
180. 2 147 3 4 5
181. 2 gt gt 115 2 2 up date
182. 31 4 WG 1 22 2 3 2 4 1 3 4 2 443 4 4 3
183. COPD Chronic Obstructive Pulmona ry Disease CAD i Medicsight CAD Ver 4 0 Pickhardt 3106 adults 6mm 93 8 90 5 77 8 Sensitivity FP 5nodule case 1 2 NIH Summers Kim
184. 1S014708 3 23 1 10 2 1 2 1 ME ME ME 2 ME ME ME 10 2 2 1S014708 3 23 2 ME ME
185. 1 224 GQP GVP
186. 10 3 21 4 WG 10 28 11 25 12 22 2 3
187. 5 A 5 B 183 qRT PCR
188. 1 RNA 3 4 2 198 3 DNA DNA 3 1 DN A DNA DNA DNA
189. 2 GMP DN A 1 2 4 1 153 DNA 2
190. 1S014708 1 14 3 1S010993 7 4 8 IS014708 3 6 8 1 8 1 1
191. 90 I I TI 21 USC 360c f 2 II 21 USC 360c a 1 B 360c e 2
192. RI OOO 3 7 4 WG 22 2 3 13 00 15 00 1 S 1 6 8 50
193. II V D 51 0 k 5 10 k 30 PMA I VD 30 PMA 171
194. RNA RNA GIU
195. RNA DNA DNA I 9
196. 2 1 2 2 26 3 12 3 1 1 WG 1 22 2 26 17 00 19 30 2 1 2 3 1 4 2 5 1 2 3 3 4
197. SE FDA 21 USC 360c i 21 CFR 807 92 a 3 5 10 k 21 CFR Part 807 Subpart E 169 5 1 0 k 1 21 CFR 807 92 a 3 1976 5 28 II 1 5 1 0 k SE 5 10 k
198. 80 1 TF WG 3 3 1 WG 21 11 4 13 00 15 00 5 C 1 6 8 50 WG O
199. MEDDEV 2 7 1 rev 3 Clinical evaluation Guide for manufacturers and notified bodies CAD 218 2 3 3 ee Rs 2 CAD 3 WG CAD
200. 8 174 indication for use RNA 5 II
201. PMA QS PMA IVDMTIA MDR 21 CFR Part 803 MDR 168 21 CFR 803 3 F DA 21 CFR 830 30 a 1 FDA 21 CFR 803 30 a 2 F D A 21
202. 7 F DA
203. ACR CLSI CLSI EP5 A CLSI EP 12A
204. Resolution No 209 154 2 0 12 1 3 DNA 1
205. 15 3 19 No 36 20 10 8 1008001 10 20 8 4 0804001 JIS 1 JIS T 0993 1 2005 1 2 JIS T 7401 1 2002 1 3 JIS T 7401 2 2002 2 Ti 6Al 4V 4 JIS T 7401 3 2002 3 Ti 6Al 2Nb 1Ta 5 JIS T 7401 4 2002 4 Ti 15Zr 4Nb 4Ta 6 JIS T 7401 5 2002 5 Ti 6Al 7Nb 7 JIS T 740
206. 4 2
207. 99 1 1 999
208. 1mm 1cm
209. A B C D 73 9 1 5 1 9
210. DN A 7 WG 4 2 8 WG WG
211. 1 2 3 4 5 6 Vn Vn o 1 4 n
212. Vectibix panitumumab Amgen Erbitux cetuximab Merck Gefitinib lressa AstraZeneca Tarceva erlotinib Roche 2009 2 27 TheraScreen KRAS PGx DNA 2 F DA AmpliChip P450 Hoffmann La Roche DNA
213. TRE Fitzpatrick n lt Fitzpatrick TRE 2 Fitzpatrick TRE TRE 105 3 3 1 1 2 i
214. ACR ACR F DA 189
215. NW I P New work item Proposal 6 JMAC J MAC JMAC ISO TC34 SC16 NW IP 162 1 4 FDA DNA FDA DNA Class Special Controls Guidance Document Drug Metabolizing Enzyme Genotyping System March 10 2005 http www fda gov cdrh oivd guida
216. I VDM IA F DA FDA 163 should l 201 h
217. 4 1 4 2 In vivo 3 10 5 WG TF 2 2 3 9 10 00 15 00 6 4 2 16 85 50 86 4 1 DBS Deep Brain Stimulation
218. Level Set iii 215 5 CAD
219. 2 2 1 CAD 2 1 1 CAD CAD CAD CAD CAD
220. 5 20 B 6 B 6
221. DN A WG DNA 2 2 DNA DNA DNA
222. 210 B CADx CAD 1 B CADW EL EE DW DI Irr DEV Horsch Ei MK 2 Chang Se 48 CadTs CADx
223. RT PCR RNA 90 110 5 2003 CLSI H1 A5
224. 1 2 PMDA TRE
225. CAD CAD 2 CAD i CAD CAD X CT 1 2 6
226. 1 I F DA a 510 k 21 U S C 360k PM A 21U S C 360e http www fda gov cdrh devadvice 3132 html I VDM I A TI IVDM IA 1 I 21 CFR 866 6040
227. 1 DNA 2 3 DNA DN A DNA DN A I VDM I A DNA FDA 203 V 7 1
228. amp 122 5 4 4 5 4 1 1998 5 4 2 accuracy correctness precision
229. WG WG WG 1 3 WG NEDO NEDO 131 WG
230. 20 BMI http brainprogram mext gojp 2 DBS
231. 3 2 3a 3 3 b c a EBM SLM ARCAM EBM S400 system ESOINT M270 SLM system 3 3D CAD Ti 6Al 4V 100 m 3 3D CAD Ti 6AL 4V 30 m 3 CAD Ti 6Al 4V 0 07 0 25mm EBM
232. D NA GMP QMS IS013485 JIS Q 13485 GMP QMS IS013485 JIS Q 13485 2 4 DN A RN A DNA
233. Instructional Design ID 1 7 lt 1 gt 1 2002 2 2003 3 Dick amp Carey 2004 4 2004 5
234. P MA FDA PMA OIVD IVDM TI A I VDM
235. 1S014708 3 6 101 102 1S014708 3 6 101 103 1S014708 3 6 101 103 8 2 1 4 5 10 2 10 2 1 10 2 1 1
236. I 21 USC 360c 2 B PMA 21 USC 360c f 2 B ii 5 1 0 k FDA PMA 170 FDA 21 USC s 360c a 1
237. 3
238. A RN A DNA R N A DNA DNA DNA RN A 193
239. PMDA 2 21 3
240. A B tailor made order made Compression Hip Screw CHS 1 6
241. 6 7 1 2 21 CFR 820 30 Subpart C 1 2
242. 65 x 1 3 000 2 500 2 000 1 500 1 000 2005 oo re C 2010 2015 4 000 3 500 3 000 2 500 2 000 1 500 1 000 500 2006 12 2008 1 66 ral Y 22 3 2 2 4 b c 4000
243. 2 3 2 2 CAD 2 2 1 CAD CAD Computer Aided Detection CADe Computer Aided Diag
244. 1 2 5 TF WG 3 8 4 WG TF 22 2 15 13 30 18 00 414 2 84 50 4 WG
245. RNA 3 3 R N A RNA R N A 5 1 0 k
246. RNA RNA 196 DN A dNTP
247. PC 3 CAD CAD a A CAD Fyr7 7 PAN ES Ey PC CAD 3
248. 19 CAD iv 2 DR Double Reading CAD SCAD CAD Karssemeijer 1 DR SCAD CAD DR
249. 21 20 21 NEDO
250. 4 O 10 WG 5 TF
251. 21 CFR 809 10 b 8 191 21 CFR 809 10 8 v and 21 CFR 809 10 b 8 vi 21 CFR 809 10 b 10
252. AFP hCG 2 CFTR DN A
253. 23 8 Cell processing center CPC D A D A Zone at gradeA Zone at grade D Pass box with decontamination Air conditioning room non control _ Monitoring room SS non control 3 Preparing room 2 lt E gt GradeD First Material gowning storage room room Grade D Grade D Cell processing room RN Grade D Gas bylinder Sample lroom Storage room Won control aane 1 CPC 1
254. IEC60601 1 1 IEC60601 1 2 1 2 IEC60601 1 8 IEC62304 IS014708 Part 1 2000 Part 3 2008 IS010993 Part 1 2009 Part 3 2003 Part 4 2002 Part 5 1999 Part 6 2007 Part10 2006 10 Part11 2006
255. 227 1 CAD Medical Imaging Technology 21 1 27 33 2003 2 CAD 63 12 1389 1395 2007 3 CAD 10 35 10 No 406 10 102 105 2008 4 CAD INNERVISION 23 8 25 29 2008 5 T W Freer and M J Ulissey Screening mammography with computer aided detection Prospective study of 12 860 patients in a community breast center Radiology 220 3 781 786 2001 6 D Gur J H Sumkin H E Rockette et al Changes in breast cancer detection and mammography recall rates after the introduction of a computer aided dete
256. RNA 185 RNA RNA 5 1 0 k RNA R N A 0D260 0D280 RNA 28S 18S R N A research use only RUO 6 B
257. 21 CFR 862 2570 i F DA FDA I 5 10 k 5 1 0 k 182 ACR 4
258. 226 d
259. BMI 79 DBS TMS BMI 3 5 5 3 1 1 WG
260. 26 V 3 4 79 V 4 102 V 5 TAIIYNIYIt 131 V 6 DN A 151 V 7 i 204 VW ci 234 I
261. FDA F DA F DA 21 CFR 820 30 Subpart C 1SO 14971 1 1 AAMI SW68 2001 8 21 CFR 807 87 e 21 CFR 809 10
262. CAD CAD CAD ii 10 CAD CAD CAD 2001 4 19 1 CAD CAD CAD 207
263. 110 IS014971
264. 12 3 28 526 12 12 28 No 29 Q amp A 17 2 16 0216001 17 2 16 0216003 17 3 31 0331038 15 2 13 0213001
265. 2 2 H 2 1 1 E 2 E 3 4 4
266. 21 CFR 809 10 179 RNA RN A R N A DNA 4 8 x 106 1 1 x 107 ml RNA
267. RT PCR 187 5 1 0 k
268. 3 4 3 4 CAD CAD CAD 2 1 CAD
269. CAD WG CAD CAD CAD CADe CADx CAD
270. 17 3 31 0331038 15 2 13 0213001 15 3 19 No 36 20 10 8 1008001 20 8 4 0804001 21 12 3 1203 1 1 2
271. TRE CT TRE Fitzpatrick TRE TRE TRE IS014971 8 1 Fitzpatrick J M West J B Maurer C R Jr Predicting error in rigid body point based registration IEEE Trans Med Im
272. 5 1 0 k FDA 21 CFR 807 87 f g 21 CFR 807 87 5 1 0 k 5 1 0 k
273. ii CAD CAD 12 Prospective study 510 1 10 5 19 5 CAD recall rate Retrospective study CAD New England Journal of Medicine CAD 7 ROC
274. 1 2 1 3 3 4 Ss
275. 0CCLS 11 O WG 7 Oo
276. 2008 2008 http www meti go jp policy mono_info_service serVice iryou_fukushi downloadfiles 200806 3 pdf Accessed 2010 01 31 2009 http www jftc mdi jp img iryou_pdf kiyaku_200906 pdf Accessed 2010 01 31 2005 8 2006 9 2008 10 2008 149 4 4 1 21 NEDO0
277. 25 V 2 1 1 2015 2500
278. 5 2 2 2 4
279. 515 PMA FDA 21USC 360e a PMA FDA 21 USC 360e c 1 P MA QS F DA HUD 21 CFR 814 Subpart H 4 000 HUD
280. 4 D _ pA 1 joCR R OCR Z R a 1 l C R l o CR R xX R 1 C A 602 ed 49 2 2 2 2 CR R EC wc R 1 E gt ee ES je x RI RI R x es y 2R R x R R R PE 2 2 x y gt 0 A gt 0 gt 0 0 lt lt oo x gt 0 1 7 Ri R2 2 0 R 2 R R 2 4 _R R gt y o E Wiop 1 CR 8 MK FT R wo w 0 Zh D 5 20 nA 0 01 Hz 100 kHz
281. 5 1 0 k Traditional 510 k 5 1 0 k Abbreviated 510 k 5 1 0 k Special 510 k F DA 5 1 0 k 5 1 0 k 3 21 CFR 862 1163 0JC 21 CFR 862 1163 ACR RN A RN ths te A ban
282. 1S014708 3 7 IS014708 1 14 1 IS011134 IS011135 89 7 2 1S014708 1 14 2 7 3
283. 5 XPS 1 Co Ni x300 3
284. 2007 10 DNA OECD 2007 5 1 SO 2 1 2 TC2 1 2 DNA 2009 1 DNA MAQC SP I DI A EU 1 2 6 151 4
285. 204 CAD CAD 2 1 2 2 1 1
286. 5 10 k 5 1 0 k 510 k 175 4 21 CFR 866 4070 NTW 21 CFR 866 4070 RNA RNA R NA RT PCR RNA 5 RNA
287. 1 8 1 2 J IS 3 1 8 7 W G 1 9 5 DNA 2 0 0 7 DN A 1 9
288. FDA 21 CFR 807 87 510 k 510 k Regulatory Requirements for Medical Devices http www fda gov cdrh manual 510kprt1 html FDA 510 k 5 1 0 k Traditional 510 k 5 1 0 k Abbreviated 510 k F DA FDA 5 1 0 k 3 510 k 5 1 0 k 21 CFR 807 87
289. CNV R N A DNA 2 0 1 0 4 0 DN AA 2 0 0 4 DNA AmpliChip CYP450 F DA
290. MRI CAD CAD 5 CT i 4 3 ii EM
291. MRI CAD CADe CADx CAD DB CAD
292. 123 85 2007 12 5 4 3 precision accuracy 1
293. CAD CAD CAD PACS Picture Archiving and Communication Systems CAD Huang PACS CAD 208 CAD CAD CADe CAD CADx
294. H 1 H 1 Ti 6A 4V Co Cr Mo ee SM PMMA 110 GPa 206 GPa 1 GPa 2 643 GPa 17 2 GPa 350 MPa 0 34 0 3 0 3 0 3 0 3 0 3 H 3 13 2 1 Vol 30 2009 p 229 232 60 1 ISO 6475 Implants for surgery Metal bone screws with asymmetrical thread and spherical under surface Mechanical requirements and test methods 2 ISO 6892 Metallic materials Tensile testing at ambient temperature 3 ISO 9585 Implants for surgery Determination of bending strength and stiffmess of bone plates 4 ASTM E8 E8M Standard Test Methods for Tension Testing of Metallic Materials 5 ASTM F382 Standard Specification and Test Method for Metallic Bone Plates 6 ASTM F384 Standard Specifications and Test Methods for Metallic Angled Orthopedic
295. ML 2 3 1 WG 3 TF 1 2009 11 30 2 WG TF WG 3 A Ver 3 33 B 5 TF 3 135 WG TF
296. 2 2 navigational system 1
297. 2 1 1 8 WG DN A WG DN AA WG MammaPrint DN A DN AA 0ncotype Dx D N A WGq DNA
298. 2007 1 9 2 F DA Agendia DNA MammaPrint IVDMIA InVitro Diagnostic Multivariate Index Assay 2007 2 AmpliChip CYP450 2009 5 2007 5 DNA HP V 2009 7 DN A DNA DNA DNA 5 1 M AQC 2005 2006 9 Nature biotechnology
299. B ROI Region of Interest ROI 1
300. CAD 2 5 1 X CT PC CAD 2
301. TI RN A RT PCR RNA 172 I RN A RT PCR RNA 2005 8 25 1 RN A RNA I RNA RNA RT PCR RNA
302. 1998 R2 Technology FDA CAD Computer Aided Detection Computer Assisted Detection Computer Aided Diagnosis Computer Assisted Diagnosis image Checker CAD X CT CAD CAD CAD CAD
303. 5 CAD 6 CAD 7 CAD 8 CAD 9 CAD 10 3 NEDO 231 4
304. 156 HER2 EGFR EGFR KRAS EGFR EGFR EGFR EGFR KRAS KRAS EGFR EGFR KRAS
305. 219 3 CAD CAD 4 5 6 CAD
306. CAD CAD CAD 10 es CAD CAD
307. vii 7 i ii iii iv vV
308. WG 82 3 5 3 WG 22 1 20 13 00 15 00 5 C 50
309. 6 3 3 6 DNA 1 E2 E2 5 1 2 0 3 0 89 0 94 1 9 0 0 1 1 0 92 0 97 150 2 0 3 1 7 2 200 1 DNA
310. JCCLS 2 SPIDIA 21 1 1 2 QIAGEN EU SPID1IA Standardisation and improvement of generic Pre analytical tools and procedures for In vitro DIAgnosteics EU 1 1 QIAGEN 4 1 3 0 0 QIAGEN HPV QIAcube 3 ISO TC21 2 2 0 6
311. 1 7
312. 124 10 1961 6 21 WG WG 1 2 Dependability MEA
313. 3 6 DN A 8 DNA 7 1 3 CAD
314. 6 Ti 15Mo 5Zr 3Al 12 JIS T 7403 1 1 13 JIS T 7403 2 2 14 JIS T 0302 15 JIST0304 16 JIS T 0306 X XPS 17 ISO 16428 Implants for surgery Test solutions and environmental conditions for static and dynamic corrosion tests on implantable materials and medical devices 36 4 5 18 1S0 16429 Implants for surgery Measurements of open circuit potential to assess corrosion behavior of metallic implantable materials and medical devices over extended time periods JIS T 0311 JIS T 0312 JIS T 0313 custom made osteosynthesis devices
315. 10 5 1 HEPA 2 6 i ii iii iv vV vi
316. 2008 2008 64 1 20 2 1
317. 2009 1 2 decontamination microorganism
318. C D JIS T 0302 JIS T 0306 D JIS T 0304 1S0 16428 1S80 16429 1S0 16428 0 9 NaCcl HC1 pH 2 JIS T 0309 10 Hz 1 10 39 8
319. FDA Federal Register February 8 2008 Volume 73 Number 27 General Hospital and Personal Use Devices Reclassification of Medical Device Data System 2008 2 1 Medical Device Data System MDDS Clinical communication devices IT components v s Medical devices Guidancel for the Submission of Pre market Notifications for Medical Image Management Devices PACS 510 k 510 k 2 0Overview of IVD Regulation LIS 510 k 2 1 510 k 2
320. 4 0JT 143 3
321. 114 2 gt gt 2 gt gt
322. dependability 125 dependability dependability dependability 6 2 TRE TRE Target registration error TRE TRE 6 3
323. ii AZE CAD 4 X CT CAD CAD CAD CT CAD 15 20 213
324. 10 DNA CV
325. D 4 R2 R1 R2 R1 C C gt D 4 X 1 JC X 2 1 1 1 1 JoCA Xor Zor R Xor R Z R O14 joCR D 4 Z x y R R CR A 2 425 2 2 2 27 1 J CR 1 CA 1 0o CR Z lt z Yzzg y 48 re R CC gt lv R CC 1 1 1 w2C2R O CR 1 w2C2R 1 C R 2 2
326. 165 1 V DM 1 A 2 0 50 18 F DA I VDM 1I A F DA TIVDM I A
327. 5 3 3 FMEA 5 3 1 FMEA FMEA Failure Mode and Effects Analysis 116 5 3 2 HFMEA Health care FMEA National Center for Patient Safety FMEA VA Veterans Affair RCA RootCause Analysis FDA HACCP Hazard Analysis Critical Control Point Decision tree HFMEA 5 3 3 1
328. F 2 F 1 OA K JIS T 0310 10 F 1 O F 1 Z F 3 a CHS Cb F 1 57 M P L coA ZZ E1 comax K oA E2 M P K omax Z x H h xC2 3 2b 6 F 2 58 G 4
329. F D A I VDM I A 21 USC 360c a 1 F DA 1 510 k PMA 1 VDM TI A 3 3 I I 21USC 360c I VDMI A I VDM I A I VDM I A
330. I II IV 44 C C 1 C 1 Cr Mo
331. 6 5 1 0 k 6 A RNA RN A
332. EBM 1 Murr LE et al Microstructure and mechanical behavior of Ti 6Al 4V produced by rapid layer manufacturing for biomedical applications Journal of the Mechanical behavior of Biomedical Materials 2009 2 20 32 2 Harryson OLA et al Direct metal fabrication of titanium implants with tailored materials and mechanical properties using electron beam melting technology Materials Science and Engineering C 2008 28 366 373 3 68 5 6 4
333. FDA HUD I VDM I A I VDM I A FD A 1 VD II 5 1 0 k OF DA 5 10 k O I VD I V D F DA 5 10 k I VD
334. 510K FDA 2 2010 1 510K 510K PMA 510K PMA 510K FDA 1 Computer Assisted Detection Devices Applied to Radiology Images and Radiology Device Data Premarket Notification 510 k Submissions 2 Clinical Performance Assessment Considerations for Computer Assisted Detection Devices Applied to Radiology Images and Radiology Device Data Premarket Approval PMA and P
335. RT PCR D 197 2 5 In Vitro Diagnostic Multivariate Index Assays I VDM IA DN A TI VDM I A I VDM IT A 1 1 V DM 1 A DNA
336. Ti 6Al 4V Ti4 Ti 15Zr 4Nb 4Ta 69 Ti4 1400 sn 20 R 0 Ti 6Al 4V a Ti 15Zr 4Nb 4Ta 7 209 on 1000 m b N 800 CN 600 400 103 104 105 106 E 3 4 Oj a 2096 10 Hz b Ti 15Zr 4Nb 4Ta ee oO or b O do 104 105 105 107 108 103 104 105 106 107 108 E 4 53 E 1 K E 2 b E 5 E 6 K 1 2b a E3
337. 9 7 ss 5 4 6 2 234 5 9
338. 2 6 2 5 B 86 5 89 8 88 3 CAD B CAD 84 iii
339. 22 3 1 CADe CAD NOW CADe 3 CAD 216 MG i R2 CAD M1000 21200BZGO0004000 12 1 31
340. ACR RN A qRT PCR RNA
341. 2 27 3 4 1
342. 220 2 4
343. 101 V 4 1 1 1
344. 2 ME 50mm 5mm gt 600kg m 1 3 ME ME 1 ME m Kg cm m gt 10 5 10 lt m 3 50 3 m gt 50 7 100
345. 2 RNA SuperScript Indirect cDNA Labeling System cDNA Cy3 cDNA cDNA 12 ml TE 4 DNA 3 cDNA DNA 65C FLA 8000 FujiFilm E2 2 8 log2 DNA 6 E2 E2 2 1 6
346. DNA 2 0 3 1 7 2 150 120 9 0 R1 R2 R3 R4 R5 1 3 4 9 0 150 90
347. pH 7 5 A260 A280 RNA RNA DN A gDNA RT PCR RT PCR RT PCR F D A 5 1 0 k RNA EN 13640 2002 RNA
348. 5 F 2 F 3 4 5 5 40 3 1 2 3 4 1 5 C
349. CAD i ii 4 4 CADe CADx iii CAD 3
350. EU DNA 1 2 3 DNA 1 DNA DN A DNA
351. RNA 176 RNA 7 RNA RT PCR
352. 2007 e 2008 7 The Learning Federation Project Component Roadmap Instructional Design in 6 Technology Enabled learning Systems Using Simulation and Games in Learning Federation of American Scientists 2003 URL http www fas org programs tp policy_and_publications roadmaps _docs 1 201Instructional 20Design doc Accessed 2010 03 01 132 2 21 2 TF 2 WG TF 2 1 1 TF 1 2009 10 26 2 WG TF WG 3 B 1
353. 3 2 3 2 1 JIS Z8103 ISO 3534 Statistics Vocabulary and symbols 1mm 1mm 1mm 1mm 1mm Wikipedia
354. RNA R N A RNA RN A Tris CI pH 7 5 260 nm A260 177 R N A RNA RNA RT PCR R N A RNA RN A
355. 4 WG 5 21 5 1 4
356. 8 4 F 12 1S014708 3 81 19 G 14 1 5 EMC 16 1 7 1 7 H 18 I 19 3 4 2 WG 41 12 16 13 00 15 00 5 C
357. IT 1 0 V 1 200 000 00 1 000 000 00 800 000 00 600
358. 4 4 1 88 4 2 4 3 5 1
359. 6 1 Dependability Dependability availability dependability dependability dependability
360. JIS H 4650 JIS H 4670 1 2 3 16 11 15 No 19 12 3 28 526 12 12 28 No 29 Q amp A 63 4 5 6 7 8 9 10 11 17 2 16 0216001 17 2 16 0216003
361. PMA CADe 3 JIRA CAD WG 5 CAD a CAD b CAD c CAD d CAD e f 3 2 2 WG 1 22 3 12 18 00 20 20 2 1 1 WG 2 CAD 3 CAD 4 CAD
362. 138 3 21 A 1 WG
363. 94 10 2 3 IS014708 1 23 3 10 2 4 IS014708 1 23 4 10 2 5 IS014708 1 23 5 10 2 6 IS014708 1 23 6 10 3 10 3 1 IEC60601 1 2 IEC60601 1 2 10 3 2 IS014708 1 25 a
364. F DA Agilent Agendia FDA MAQC project http www fda gov ScienceResearch BioinformaticsTools MicroarrayQual ityControlProj ect default htm MAQC 11 MAQC 1 I I I 3 MAQC I QC MAQC I I MAQC I I I SEQC MAQC MAQC II 2009 9 Nature Biotechnology 1 0 Manuscript MAQC 111 also known as SEQC The third phase of the MAQC project MAQC II also called Sequencing Quality Control SEQC aims at assessing the technical performance of next generation sequencing platforms by generating benchmark datasets with reference samples and evaluating advantages and Iimitations of various bioinformatics strategies in RNA and DNA analyses
365. 3 B A A 2 C B A 1 D C B lt 1 D D C A B 6 118 D A B C D A B GC D 7 8 9
366. DNA 7 1 1 7 WG 2 2 http www meti go jp policy mono_info_service service iryou_fukushi index html
367. E 1 Z E 3 3 2 5 10 0 2 0 4 0 6 0 8 1 0 0 0 5 1 2b H 2r H E 5 E 6 E 3 4 ja Co ax 9 ag E 1 E 2 as o E 3 E 7 E 8 E 8 P qa gp Kelven oqo 4T k T k amp o Cp 8 27 Pa T K k
368. PMA Premarket Approval 510K SS RN CAD LLZ X 510K i CADe 3 510K a NWE b 0EB c OMJ X 217 ii CADx PMA
369. 1 2 RN A 3 RNA R N A cCDNA R N A
370. 1 6 8 50 11 5 WG WG IS0 amp TMS BM I
371. 10 11 12 5 3 4 FMEA HFMEA 119 HFMEA 121 HFMEA Dependability Fiducial Marker Target 8 2 A Registration Error
372. 103 2 3 devices for precision surgery 2007 2 4 quality of navigation IFIP WG10 4 n DEPENDABLE COMPUTING AND FAULT TOLERANCE The notion of dependability defined as the trustworthiness of a computing system which allows reliance to be justifiably placed on the service it delivers enables these various concerns to be subs
373. 2 3 4 5 6 6 IS014708 1 5 IEC60601 1 IEC60601 1 2
374. B 2 C 11 13 ML 133 B 3 2 2 2 TF 1 2 3 2009 11 13
375. 2 20 21 20 127
376. 3 4 1 2 3 4 1 2 3 3 1
377. DNA DN A JC 1 JCCLS 1 2 5 DNA DN A 2 2 1 3 DNA
378. CAD i CAD CAD CAD 1998 CAD R2 Technology HOLOGIC 206 iCAD CAD CAD 10 R2 CAD 2000 2 GE CAD R2
379. ON a NTC Guastaldi AC Electrochemical stability and corrosion nce of Ti Mo alloys for biomedical applications Acta Biomaterialia 2009 5 1 6 405 4 34 b 60 7z 1 156 150 7 7 3 1989 1992 1999 2002 2005 2006 2007 2008 2009 9 60 2 Archives of Orthopaedic and Trauma Surgery Acta Chirurgiae orthopaedicae et Traumatologiae eechoslovaca Acta Orthopaedica Clinical Orthopaedics and Related Research International Orthopaedics The Journal of Arthroplasty The Journal of Bone Joint Surgery Am Br Revue Chirurgie Orthopedique et Reparatrice de Appareil Moteur Zeitschrift fur Orthopadie und ihre Grenzgebiete 5 5 2
380. GHTF a CAD 3 4 9 10 X MR I b CAD 5 F DA CADe
381. 3 4 4 5 F 6 41 6 1 2 3 4 42 1 F 2 G 3 4 A A 1
382. b c IS014708 1 25 95 10 3 3 IS014708 3 26 1S014708 1 26 2 10 3 4 IS014708 3 20 10 3 4 1 a IS014708 1 20 1 b
383. 10 26 11 13 2 1 11 3 0 2 2 1 1 3 DNA 2 2 2 17 ee 2 6 3 1 2 13 V DNA ON 14 V 1 1 in vitro
384. 17 1 7 ii GEHC CAD SLD 21900BZY00043000 19 4 9 PE CAD MV SR657 0 21900BZZ00041000 19 12 4 iv CAD NEOVISTA CAD typell 22200BZX00278000 22 3 17 2 3 2 1 CAD FDA R2 1998 6 FDA iCAD CADx iCAD CAD 2004 11 FDA R2 iCAD CAD R2 HOLOGIC 510K Premarket Notification 510 k Submissions
385. 2009 5 12 MammaPrint Agendia 7 0 2007 2 I VDMIA 157 Pathwork Tissue of Origin test 1 5 2008 7 31 MammaPrint 2 I V DM I A TessArray 2 0 09 12 16 2010 4 2 FDA Emergency HPV Roche AmpliChip CYP450 DNA 1 5 0 0 0 DNA CYP2C19 3 CYP2D6 2 7 100ng DNA CYP2C19 CYP2D6 8
386. PMA I 21 USC 360c i 0 I VD II II 21 USC 352 o
387. sterile sterilisation disinfection aseptic processing pass box with decontamination lsolator system D
388. 3 DNA JCCLS 4 1 2 5 DNA 1 3 DNA 1 2 6 1 2 1 2 3
389. IVD F DA IDE F D A FDA 0 I VD IDE 3 I VDM IA 21 CFR Part 820 QS F DA 1988 CLIA QS F D A 05 I VDM1IA F DA QS
390. RNA RNA RN A R N A RT PCR RN A F D A RNA
391. WG 2 1 3 PC
392. ii 2cm 1cm
393. n 1 1 MAQC FDA 2005 2 2006 9 ERCC External RNA Control Consortium MAQC I 1 FDA 2006 9 2009 3 I SO TC2 12 OEC D CEN EME A Affymetrix Roche
394. 10 A cm Ti JIS T 7401 2 Ti 6Al 4V JIS T 7401 4 Ti 15Zr 4Nb 4Ta 316L 10 WA cm pH D 2 IS0 16428 1S0 16429 0 9 NaCl pH 5 6 pH 5 5 MEM pH 7 5 PBS pH 7 5 1 8 NaCl 2 7 NaCl 3 6 NaCl 4 5 NaCl 0 9 NaCI HCI pH 1 2 3 4 5 6 0 01 pH 3 5 0 05 pH 3 1 pH 2 0 01 HCI pH 2 pH 7 4 pH 6 4 10 WA cm T 10 WA cm 1 we je D 1 46 10 A cm 4 3 Ti 6AI 4V 2F HH
395. Monitoring room 1 First gowning room Preparing room Material storage room Cell processing room Sample storage room Air conditioning room amp 9 Gas cylinder room 24
396. 2 CADe 212 i FDA CAD R2 Technology Image Checker CT Siemen Lung Care CT Nodule Enhanced Viewing NEV 4mm Solid nodule Das Radiology 2006 Image Checker CT NEV 25 Sensitivity 73 75 FP False Positive 6 nodule case 8 nodule case Chicago Univ Armato Cornell Univ Reeves UCLA McNitt Gray Univ Medical Center Utrecht Sluimer Sluimer CT IEEE TMI 2006 ji CAD CAD 3 5mm Sensitivity 91 1 FP 1 32nodule case
397. 3 2009 1 1 4 3
398. 1 0 V vs SCE D 2 pH D 2 XPS XPS D 3 X 6 d d 3Asin IMFP 2 Ti0 2 nm d Ti0 4 23 g cm Ti0 16 3 eV 3 2 eV 3eV D 3 XPS 47 D 3 JIS T 0302 Ti 0 01 Hz 100 kHz 1 Hz 1 kHz
399. 2 4 2 WG 4 TF 1 2010 01 13 2 WG TF WG 3 Ver 4 1 A
400. 2003 12 iCAD CAD CAD 2007 12 CR CAD 2008 2 2010 3 CAD 2009 2 CAD R2 iCAD CAD 100 10 60 CAD
401. 1S014708 1 20 2 10 3 4 2 IS014708 1 21 10 3 4 3 IS014708 3 22 IS014708 1 22 96 Append ix
402. 9 1 1 9 1 2 IS014708 1 15 2 9 2 IS014708 3 16 91 1 IS014708 3 16 2 9 2 2 9 2 3 9 3
403. QOL Quality of Life QALY Quality Adjusted Life Years CAD 1 CAD CAD 2
404. ACR 5 1 0 k F D A
405. CAD GHTF The Global Harmonization Task Force CAD GHTF 205 CAD 3 4
406. 2 1 2 1 2 2 3 QOL
407. 20 TST 0011 1 ISO 5832 1 Implants for surgery Metallic materials Part 1 Wrought stainless steel 2 ISO 5832 2 Implants for surgery Metallic materials Part 2 Unalloyed titanium 3 ISO 5832 3 Implants for surgery Metallic materials Part 3 Wrought titanium 6 aluminium 4 vanadium alloy 4 ISO 5832 11 Implants for surgery Metallic materials Part 11 Wrought titanium 6 aluminium 7 niobium alloy 5 ISO 7153 1 Surgical instruments Metallic materials Part 1 Stainless steel 6 ASTM A276 Standard Specification for Stainless Steel Bars and Shapes 7 ASTM F67 Standard Specification for Unalloyed Titanium for Surgical Implant Applications UNS R50250 UNS R50400 UNS R50550 UNS R50700 8 ASTM F75 Standard Specification for Cobalt 28Chromium 6 Molybdenum Alloy Castings and Casting Alloy for Surgical Implants UNS R30075 9 ASTM F90 Standard Specification for Wrought Cobalt 20Chtomium 15Tungsten 10Nickel Alloy for Surgical implant Applications UNS R30605 62 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ASTIM F136 Standard Specification for Wrought Titanium 6Aluminum 4Vanadium ELI Extra Low Interstitial Alloy for Surgical Implant Applications UNS R56401 ASTM F138 Standard Specification for Wrought 18Chromium 14Nickel 2 5Molyb
408. 4 O 1 2 9 4 5 6 7 8 9 6
409. CAD CAD CT Information and Communication Technology I CT Error Proof
410. CADx ROC CAD CAD CAD CAD CAD CAD CAD CAD Second Reader CAD CAD CAD concurrent CAD CAD CAD
411. DNA HPV DNA 2 1 3 HP V DNA 2 3 PV DNA 2 4 HPV DNA 3 JMAC 1 159 1
412. IS014708 3 17 9 4 IS014708 3 19 9 4 1 IS014708 1 19 1 9 4 2 IS014708 3 19 2 9 4 3 IS014708 3 19 3
413. IS014708 3 19 3 92 9 5 9 6 In vivo 2 1 WG http dmd nihs go jp jisedai neuro index html In vivo
414. N 20 Ti 0 Fe 4 Ti 20 Ti Ti Mo Zr Nb Ta Ti NSVYIN C 1 45 D D 1 C1 D 1
415. RNA 194 y DNA DNA
416. 4 ROC area under the receiver operating characteristic ROC curve AUC ACR
417. DN A 2 0 0 6 2 0 0 7 DNA JMAC JCCL S JBA JCI 2 0 0 6 2007 DNA 2007 DNA 2007 5 DN A TS 1 9 2008 3 DNA 0404002 2008 4 4 152 D N A yy 0OD 1 11 lt 2 2 DNA
418. G 1 G 1 E 2 G 2 12m r d 1 P P h k 3 M P h 2 o max Z G 1 M da4_ d G2 omax 32 ds Z G 1 4 rd 1 R E Peterson Stress Concentration Design Factors John Wiley amp Sons TNC New York p 36 59 H H 1 H 2
419. WG TF WG 1 Ver 1 2 B 4 UPS
420. Part12 2008 12 IS014971 97 7 7 2 eo oo 9g 1 cm 5 0 5 37 C 2 8 lt 18
421. 2 22 2 16 3 2 2 1 2 WG NN 22 2 16 18 00 20 00 1 2 3 3 1
422. 23 1S0 16428 Implants for surgery Test solutions and environmental conditions for static and dynamic corrosion tests on implantable materials and medical devices 24 1S0 16429 Implants for surgery Measurements of open circuit potential to assess corrosion behavior of metallic implantable materials and medical devices over extended time periods 70 8 1 I MV 71
423. CRMGEN2005 Certified Reference Materials for Molecular Genetic Testing UROGENTET JCTLM 1 1 4 2009 2 DNA R N A RN A R N A 0 R N A RNA
424. 3 CPC GMP 10 24 18 18 CPC 5
425. 1 Pa T K 1 K p kg m Cp J kg K 4T o 4 0 92 54 Ti 3 58 x 1012 Ti 6Al 4V 3 83x10 Pa Ti 8 4x10 Ti 6Al 4V 8 8x10 1 K Ti 4 51 x10 Ti 6Al 4V 4 42x10 kg m Ti Ti 6Al 4V 0 52 x10 J kg K 870 880 484 483 E 7 4 900 max 800 onsx 700 600 500 400 AB MPa Ag ag 200 3
426. MDD Guidelines for the qualification and classification of software used in health care as medical devices Version of February 4 2010 MD D 2010 2 Medication Modules MANUAL ON BORDERLINE AND CLASSIFICATION IN THE COMMUNITY REGULATORY FRAMEWORK FOR MEDICAL DEVICES PACS 1 2a 2b 222 TPD Classification of Medical Devices Class or Class patient management software Patient management software 1 2 3
427. QF NvVHENGHS ORL si AN RtN 9 MIN 3 WG 1 WG 2 WG 3 WG 4 WG 5 WG 6 DNA 7 NM 4 WG O 1
428. ID 6 1 11 30 10 5 50 1 3 4
429. 22 4 WG 2 2 2 3 3 1 WG 2 1 11 4 2 WG 2 1 12 16 3 WG 2 2 1 20 4 WG 2 2 2 3 5 WG 2 2 2 24 1 TF 2 1 10 19 2 TF 2 1 10 27 3 TF 2 2 1 25 4 TF 2 2 2 15 5 TF 2 2 3 9 4 1 WG 2 1 11 18 2 WG 2 1 12 4 2 1 11 26 5 1 TF RC 2 1 2 1 1 WG 3 TF 2 WG 4 TF 6 1 1 WG 7 1 WG 2 WG 2 2 2 2
430. 3 1 D ISO 8 2 21 3 4 5 6 7
431. CAD computer aided diagnosis 209 CADe computer aided detection CADx CAD ii CAD B B CAD B B CAMW Medi
432. DR Gilbert SCAD DR 6 5 1 CAD CAD CAD CAD Gilbert DR SCAD SCAD RE v CAD CAD CAD
433. MAQC 1I I I 160 DNA WG WG DNA
434. 1 TF 2 TF IS014708 2 A 1 3 1 SCOPE 2 B 2 C 5 D 7 E 8
435. 2 MammaPrint F D A RNA 3 8 Tissue of Origin Test F DA Pathwork Tissue of Origin test 2008 7 31 1 5 IVDM I A 4 7 7 8 9 9 158 8 9 29 WMonzon FA et al Association for Molecular Pathology Annual Meeting 2007 Abstract T02 FDA 2007 7 in vitro diagnostic multivariate index assay I VDM TI A MammaPrint 2 I VDMIA Te
436. 78 V 3 1 16 19 1950 BMI Brain Machine Interface BCI Brain Computer Interfac
437. IVDMTIA 1 FDA I VDM I A I VDM 1 A 1 VDMI A 1
438. P p Pp h h E 1 4 a ee b M P h 2 co Ap 2 E 1 O max KK oAB E 2 M P max AB K A B 0o AB AB 2a omax Z 2b 1 Z x H h xC2 E 3 E 2 52 MPa E 1 K JIS T 0310 10 E 1 Oj 4 Oj E 3 E 4 K 3
439. WG 5 18 11 24 WG 6 1 9 5 2 1 1 8 WG 1 9 7 2 0 3 2 4 WG 8 2 1 3 17 WG 9 2 2 3 15 2 1 7 7
440. 510k CADx PMA c CAD 6 7 CAD d 1 3 4 8 CAD
441. Part 9 Framework for identification and quantification of potential degradation products 61 9 ISO 10993 10 Biological evaluation of medical devices Part 10 Tests for irritation and delayed type hypersenstivity 10 ISO 10993 11 Biological evaluation of medical devices Part 11 Tests for systemic toxicity 11 ISO 10993 12 Biological evaluation of medical devices Part 12 Sample preparation and reference materials 12 ISO 10993 13 Biological evaluation of medical devices Part 13 Identification and quantification of degradation products from polymeric medical devices 13 ISO 10993 14 Biological evaluation of medical devices Part 14 Identification and quantification of degradation products from ceramics 14 ISO 10993 15 Biological evaluation of medical devices Part 15 Identification and quantification of degradation products from metals and alloys 15 ISO 10993 16 Biological evaluation of medical devices Part 16 Toxicokinetic study design for degradation products and leachables 16 ISO 10993 17 Biological evaluation of medical devices Part 17 Establishment of allowable limits for leachable substances 17 ISO 10993 18 Biological evaluation of medical devices Part 18 Chemical characterization of materials 18 JIS T 0993 1 1 19 JIS T0301
442. TS DN A D NA DNA DNA DN A IV DM I A 2 1 DN A 1 2 DNA 1 2 1
443. 000 00 400 000 00 200 000 00 000 Ii 7 8 9 10 11 12 13 14 15 16 17 18 19 20
444. 150 DNA 3 5 1 Inoue A Yoshida N Omoto Y Oguchi S Yamori T Kiyama R and Hayashi S 2002 Development of cDNAmicroarrayfor expressionprofiling of estrogen responsive geneSs J Mol Endocrinol 29 175 192 2 Terasaka S Aita Y Inoue A Hayashi S Nishigaki M Aoyagi K Sasaki H Wada Kiyama Y Sakuma Y Akaba S Tanaka J Sone H Yonemoto J Tanji M and Kiyama R 2004 Expression profiling of the estrogen responsive genes for evaluation of estrogen activity among natural estrogens and Industrial chemicals using a customized DNA microarray Environ Health Persp 112 773 781 3 lse R Han D Takahashi Y Terasaka S Inoue A Tanji M and Kiyama R 2005 Expression Profiling of the Estrogen Responsive Genes in Response to Phytoestrogens Using a Customized DNA Microarray FEBS Lett 579 1732 1740 4 Terasaka S Inoue A Tanji M and Kiyama R 2006 Expression profiling of estrogen responsive genes In breast cancer cells treated with alkylphenols chlorinated phenols parabens or bis and benzoylphenols for evaluation of estrogenic activity Toxicol Lett 163 130 141 201 5 Dong S Inoue A Zhu Y Tanji M and Kiyama R 2007 Activation of rapid sig
445. CFR 830 50 a I VDM 1 A lI VDM I A MDR FDA IVDMI A I VDM I A F DA 12 FD A I VDM I A 12 510 k PMA FDA I VDM1IA 6 F DA 1 8 I VDM I A
446. Fracture Fixation Devices 7 ASTM F543 Standard Specification and Test Methods for Metallic Medical Bone Screws 8 ASTM F2180 Standard Specification for Metallic Implantable Strands and Cables 9 JIS Z 2241 10 JIS G 0577 11 TST0013 12 JIS T0305 1 ISO 10993 1 Biological evaluation of medical devices Part 1 Evaluation and testing within a risk managememt process 2 ISO 10993 2 Biological evaluation of medical devices Part 2 Animal welfare requlrements 3 ISO 10993 3 Biological evaluation of medical devices Part 3 Tests for genotoxicity carcinogenicity and reproductive toxicity 4 ISO 10993 4 Biological evaluation of medical devices Part 4 Selection of tests for interactions with blood 5 ISO 10993 5 Biological evaluation of medical devices Part 5 Tests for in vitro cytotoxicty 6 ISO 10993 6 Biological evaluation of medical devices Part 6 Tests for local effects after 1implantation 7 ISO 10993 7 Biological evaluation of medical devices Part 7 ERthylene oxide sterilization residuals 8 ISO 10993 9 Biological evaluation of medical devices
447. I A FDA IVDM I A IVDM1IA IVD 21 CFR 809 10 I VDM 1 A 21 CFRS 809 10 a FDA IVDM IA IVDMTIA
448. Oliveira A C Guastaldi Electrochemical stability and corrosion resistance of Ti Mo alloys for biomedical applications Acta Biomaterialia 2009 5 1 399 405 5 p 99 6 p 53 51 E 4 E 1 JIS T 0312 L N 10 E 2 4 E 1 P k
449. TF 21 10 19 9 00 15 00 I 2 16 1 2 1F 50 1S014708 3 2009 4 FDA DE 3 2 2 WG TF 2 1 10 27 9 00 16 00 6 2 15 4 1 50
450. 00 400 500 600 700 800 P N E 8 osa oi 55 1 A4 p 27 2 p 205 3 p 362 4 JIS T 0310 5 NDIS 3425 2008 6 JIS Z 2300 2009 p 84 p 87 56 F F 1 JIS T 0313 L N 10 F 2 1 F 2 E 3 K K 1 2b a K
451. 1 6 2002 6 Ti 15Mo 5Zr 3Al 8 JIS T 7402 1 2005 1 9 JIS T 7402 2 2005 2 10 JIS T 7402 3 2005 3 77 11 12 3 4 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 JIS T 7402 4 2005 4 JIS T 7403 1 2005 JIS T 7403 2 2005 JIS T 0301 2000 JIS T 0302 2000 JIS T 0303 2000 JIS T 0304 2002 JIS T 0305 2002 JIS T 0306 2002 JIS 6 0577 2005 JIS Z 2241 1998 JIS Z 2244 2009 JIS K 7113 1995 TS T 0011 2008 TS T 0013 2009 JIS T 3009 2009 JIS T 3010 2009 JIS T 3011 2009 JIS T 3012 2009 JIS T 0313 2009 1 2
452. 14 E Mail human ws m aist go jp
453. 2 I VDM I A I VDM I A I VDM I A I VDM I A I VDM 1 I VDM I A
454. 2 RNA FDA 173 1 21 CFR 807 Subpart E the act 2 0 F DA Substantial Equivalence SE RNA 4 RNA 5 10 k
455. 2 1 2C R 1 WC R 2 2A A R Z R 1 C A 1 C A C A 0 Z V Ri R R R 1 w C R2 oo 2 R R 2 0 1 w2C2R YR R HZ 5000 Prinston Applied Research PARSTAT2273 20 nA 10 mV 0 01 Hz 100 kHz Q Nyquist 5 D Echem Soft Ware 7simpWin
456. 237 2 444 449 2005 228 15 16 F J Gilbert S M Astley M A McGee et al Single reading with computer aided detection and double reading of screening mammograms in the United Kingdom National Breast Screening Program Radiology 241 1 47 53 2006 CAD CAD 27 CD ROM B2 02 2008 17 A H T Le B Liu and H K Huang Integration of computer aided diagnosis detection CAD 18 19 20 21 results in a PACS environment using CAD PACS toolkit and DICOM SR International Journal of Computer Assisted Radiology and Surgery 4 4 317 329 2009 4 42 4 364 365 2010 http www medipattern com solutions_bcad asDx Medipattern B CADTM BI RADS 21 R 21 2008 C M Chen Y H Chou et al Breast lesions on sonogram Computer aided diagnosis with nearly setting Independent features and artificial neural networks Radiology 226 2 504 514 2003 22 K Horsch M L Giger et al Compute
457. 971 2000 145 5 2
458. Biomarkers Exploratory Biomarkers Valid non Valid 155 Affymetrix DMET rx Plus Premier Pack Scanner 3000 7G Plus Targeted Genotyping System Agilent Agilent DNA amp lllumina lllumina BeadXpress System PGx Irinotec
459. CAL SURGERY 2008 36 11 130 V 5 1 1 1 20 WG WG WG lls 1 2 21 WG 20
460. D A 2 351 HIV HCV I VDM 1 A 1 V DM IA
461. DN AA DNA CYP450 2009 5 12 DN A DNA MammaPrint Agendia FDA 2009 2 6 DNA 3 5 2 0 0 9 2 3 DNA DNA SPIDIA Standardization and improvement of generic pre analytical tools and procedures for in vitro diagnostics MAQC 1I I MicroArray Quality Control
462. DNA 186 R N A RNA Cut off
463. I VDM I A I VDMI A TIVDM 1 A 1 V D 21 CFR 809 10 b FDA I VDM 1 A IVDMI A FDA 1IVDM I A CLIA FDA 1 4 2 FDA 2 FDA I
464. MG 32 A B C D E 4 F G 4 H
465. T 7401 4 2009 4 Ti 157r 4Nb 4Ta 9 JIS T 7401 5 2002 5 Ti 6AIl 7Nb 10 JIS T 7401 6 2002 6 Ti 15Mo 5Zr 3Al 11 JIS T 7403 1 2005 1 12 JIS T 7403 2 2005 2 13 JIS T 0301 2000 14 JIS T 0302 2000 15 JIS T 0304 2002 16 JIS T 0305 2002 17 JIS T 0306 2002 X XPS 18 JIS 6 0577 20050 19 JIS Z 2241 1998 20 JIS Z 2244 2000 21 JIS T 0993 1 2005 1 22 TS T 0011 2008
466. aging 1998 17 5 694 702 2 MEDICAL IMAGING TECHNOLOGY 2004 22 2 74 3 Wiles Andrew D Thompson David G Frantz Donald D Accuracy assessment and interpretation for optical tracking systems Medical Imaging 2004 2004 421 32 4 WG 17 2006 http www aist go jp aist_j aistinfo report entrust iryoukiki 2005 techrep_surgicalrobot_ft2005 pdf 5 2006 89 2 144 129 6 2006 62 12 1629 7 QA 2006 8 ST 2006 9 NEUROLOGI
467. an Warfarin Herceptin EGFR UGT1A1 Irinotecan Irinotecan Camptosar 1 U GT uridine diphosphateglucuronosyItransferase 1 A 1 28 UGT 1 A 1 Pharmacogenetics Geneva CIOMS 2005 10 UGT1A1 1 1 50 0 UGT1A1 1 28 40 12 50 UGT1A1 28 28 10 50 Clinical pharmacology metabolism and excretion Warning Dosage and administration CYP 2C9 2004 VKORC1
468. ction system Journal of National Cancer Institute 96 3 185 190 2004 7 R Birdwell P Bandodkar and D Ikeda Computer aided detection CAD with screening mammography in a university hospital setting Radiology 236 451 457 2005 8 MJ Morton DH Whaley KR Brandt et al Screening mammograms Interpretation with computer aided detection Prospective evaluation Radiology 239 375 383 2006 9 JC Dean and CC llvento Improved cancer detection using computer aided detection with diagnostic and screening mammography Prospective study of 104 cancers AJR 187 July 20 28 2006 10 JM Ko MJ Nicholas JB Mendel et al Prospective assessment of computer aided detection in interpretation of screening mammography AJR 187 1483 1491 2006 11 J J Fenton S H Taplin P A Carney et al Influence of computer aided detection on performance of screening mammography New England Journal of Medicine 356 14 1399 1409 2007 12 S Giatto N Houssami D Gur et al Computer aided screening mammography Gorrespondence New England Journal of Medicine 357 1 83 85 2007 13 N Karssemeijer J D Otten A L Verbeek et al Computer aided detection versus Independent double reading of masses on mammograms Radiology 227 1 192 200 2003 14 L A L Khoo P Taylor and R M Given Wilson Computer aided detection in the United Kingdom National Breast Screening Programme Prospective study Radiology
469. denum S tainless Steel Bar and Wire for Surgical Implants UNS S31673 ASTM F139 Standard Specification for Wrought 18Chromium 14Nickel 2 5Molybdenum S tainless Steel Sheet and Strip for Surgical Implants UNS S31673 ASTM F620 Standard Specification for Alpha Plus Beta Titanium Alloy Forgings for Surg1cal Implants ASTM F621 Standard Specification for Stainless Steel Forgings for Surgical Implants ASTM F648 Standard Specification for Ultra High Molecular Weight Polyethylene Powder and Fabricated Form for Surgical Implants ASTM F799 Standard Specification for Cobalt 28Chromium 6Molybdenum Alloy Forgings for Surgical Implants UNS R31537 R31538 R31539 ASTM F1091 Standard Specification for Wrought Cobalt 20Chromium 15tungsten 10Nickel Alloy Surgical Fixation Wire UNS R30605 ASTM F1314 Standard Specification for Wrought Nitrogen Strengthened 22Chromium 13Nickel 5Manganese 2 5Molybdenum Stainless Steel Alloy Bar and Wire for Surgical Implants UNS S20910 ASTM F1472 Standard Specification for Wrought Titanium 6Alummum 4Vanadium Alloy for Surgical Implant Applications UNS R56400 JIS G 4303 JIS G 4305 JIS G 4308 JIS G 48309 JIS G 4314 JIS G 4315 JIS H 4600
470. e BMI National Institutes of Health NIH National Institute of Neurological Disorders and Stroke NINDS Deep Brain Stimulation DBS NIH Neuromodulation DBS Spinal Cord Stimulation SCS Functional Electrical Stimulation FES Neuro Controlled Drug Delivery CDD
471. naling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF 7 cells by the treatment with an extract of glycyrrhiza glabra root Food Chem Toxicol 45 2470 2478 6 ParveenM Inoue A lse R Tanji M and Kiyama R 2008 Evaluation of estrogenic activity of phthalate esters by gene expression Drofiling using a focused microarray EstrArray Environ Toxicol Chem 27 1416 1425 7 Parveen M Zhu Y and Kiyama R 2009 Expression profiling of the genes responding to zearalenone and its analogues using estrogen responsive genes FEBS Letters 583 2377 2384 8 Dong S and Kiyama R 2009 Characterization of estrogenic activity of ginsenosides in MCF 7 cells using a customized DNA microarray Food Chem 113 672 678 9 Xu Q Hamada T Kiyama R Sakuma Y and Wada Kiyama Y 2008 Site specific regulation of gene expression by estrogen in the hypothalamus of adult female rats Neurosci Letts 436 35 39 10 Inoue A Tanji M and Kiyama R 2006 Focused Microarray Analysis Characterization of Phenomes by Gene Expression Profiling Current Pharmacogenomics 4 245 260 202 4 1 JMAC 1 2 5
472. nce 1551 html Class Special Controls Guidance Document Gene ExpressionProfiling Test System for Breast Cancer Prognosis May 9 2007 http www fda gov cdrh oivd guidance 1627 html In Vitro Diagnostic Multivariate Index Assays IVDMIA Sept 7 2006 http www fda gov cdrh oivd guidance 1610 html Recommendations for the Generation and Submission of Genomic Data November 7 2006 http www fda gov cder genomics events htm 1 4 1 FDA 1 FDA II FDA FDA 2007 7 2 6 I VDM 1 A
473. nosis CADx CADe CADx CAD mammography X CAD 1998 6 FDA CAD R2 Technology CAD X CT CT CT MRI MRI CAD IT 1 CAD 2 2 2 1
474. ompression Hip Screw CHS 1 2 3 4 5 120 lt 150 6 1 E 2 G 3 1 JIS T 0311 F F
475. pattern CAD FDA 2006 B CADW 1 ROI BI RADS Breast Imaging wa P Deat ml mlsewl Em Reporting and Data System 1 B CAD MW 14 000 1cm 1 B CAD GE
476. remarket Notification 510 k Submissions 2 MDD Medical Device Directive CAD MANUAL ON BORDERLINE AND CLASSIFICATION IN THE COMMUNITY REGULATORY FRAMEWORK FOR MEDICAL DEVICES Version 1 5 09 2009 MDD PACS Automatic Indication Detection of Potential Lesions CAD PACS X CAD Ilb lla llIb lla
477. rizeddiagnosis of breast lesions on ultrasound Med Phys 29 2 157 164 2002 23 R F Chang W J Wu et al Super vector machines for diagnosis of breast tumors on US images 24 Acad Radial 10 2 189 197 2003 21 R 23 2008 132 135 1998 25 Chou Y H TiuC M Chen J Chang R F Automated Full field Breast Ultrasonography The Past and The Present J Med Ultrasound 15 1 2007 26 Y Ikedo D Fukuoka T Hara H Fujita E Takada T Endo and T Morita Development of a fully automatic scheme for detection of masses in whole breast ultrasound Images Medical Physics 34 11 4378 4388 2007 27 A lto E Ueno E et al BreastDisease Clinical Application of Ultrasound Elastography for Diagnosis Radiology Vol 239 pp 341 350 2006 28 M Yamazaki H Takizawa 1 Shiina Computer aided Diagnosis of Diffuse Disease based on Ultrasound Elasticity Images 2008 IEEE International Ultrasonics Symposium Proceedings DDp 2033 2035 2008 229 3 21 CAD
478. ssArea LLC TessArray TessArray RM Flu H 1N 1 F DA Emergency use 2010 4 2 6 2009 12 1 6 HPV HP V 1 3 HP V HPV HPV HP V HPV LAMP DN A HPV DNA 2 5 1 LAMP
479. tation of Sections 28 to 31 License Application Type 2005 1 Therapeutic Goods Act 1989 GHTF SG1 2005 5 Information Document Concerning the Definition of the Term Medical Device 2007 2002 221 PACS IT Information Technology
480. umed within a single conceptual framework Dependability thus includes as special cases such attributes as reliability avallability safety security http www dependability org wg10 4 2 5 dependability of navigational system 104 2 6 Target Registration Error TRE target
Download Pdf Manuals
Related Search